Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II, Open-label, Multicenter Study Investigating Efficacy and Safety of Pembrolizumab +/- UV1 Vaccination as First Line Treatment in Patients With Inoperable Advanced or Metastatic Non-small Cell Lung Cancer

NCT05344209 is registered in ClinicalTrials.gov with Vestre Viken Hospital Trust as lead sponsor.

NCT NCT05344209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05344209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II, Open-label, Multicenter Study Investigating Efficacy and Safety of Pembrolizumab +/- UV1 Vaccination as First Line Treatment in Patients With Inoperable Advanced or Metastatic Non-small Cell Lung Cancer
Lead sponsor
Vestre Viken Hospital Trust
Phase
Phase 2
Overall status
Recruiting
Start date
August 12, 2022
Completion date
July 1, 2027
Enrollment
138 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc stage iv, nsclc, stage iii, oncology